Red Cell Aplasia in Chronic Kidney Disease Patient Treated with Erythropoietin : A Case Report

2014 ◽  
Vol 21 (2) ◽  
pp. 64-66
Author(s):  
Hussien Al Shebli ◽  
Ayham Haddad ◽  
Munthir Hijazat
2020 ◽  
Vol 7 (1) ◽  
pp. 14-16
Author(s):  
Md. Adnanul Alam ◽  
Muhammad Jamal Uddin ◽  
Abed H Khan ◽  
Shohael M Arafat

2019 ◽  
Vol 16 (3) ◽  
Author(s):  
Nagaraju Vallepu ◽  
Saikiran Velpula ◽  
Bharathkumar Dasari ◽  
Mahalaxmi Pykarao ◽  
Shyamsunder Anchuri ◽  
...  

2021 ◽  
Vol 15 (2) ◽  
pp. 17
Author(s):  
A. Karunatilaka ◽  
T. Hewageegana ◽  
N. Y. Perera ◽  
C. Kumarasinghe ◽  
D. Sinharachchi

2018 ◽  
Vol 2 (1) ◽  
pp. e1-e14
Author(s):  
Suzanne Morony ◽  
Angela C. Webster ◽  
Rachelle Buchbinder ◽  
Suzanne Kirkendall ◽  
Kirsten J. McCaffery ◽  
...  

2021 ◽  
pp. 1-4
Author(s):  
Sijia Li ◽  
Xueqin Chen ◽  
Penghua Hu ◽  
Suijing Wu ◽  
Jianchao Ma ◽  
...  

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.


Sign in / Sign up

Export Citation Format

Share Document